Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization. The main questions it aims to answer are: Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients? Participants will: Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms. Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.

Timeline

Start

2026-04-01

Primary completion

2028-04-01

Completion

2028-04-01

Drugs

Indications